Delivering Value Beyond the Trial with Real-World Evidence

June 30, 2025

Edward Ahn

, Rob Philo

Rob Philo

, Shana Gunderson Hua PharmD

Shana Gunderson Hua PharmD

, Ed Schoonveld

Ed Schoonveld

Sponsored

Peer Exchange | <b>Unlocking Strategies for Navigating the Evolving Market Access Landscape: A Pharmaceutical Commerce Peer Exchange®</b>

In response to the rising importance of real-world evidence (RWE) in showing value to payers beyond traditional clinical trials, key opinion leaders emphasize finding cost-effective approaches, considering diverse patient populations, and using AI to pinpoint which patients will benefit most from treatment.

Real-world evidence (RWE) is no longer optional—it's expected. This episode dives into how payers assess RWE alongside clinical trial data, especially in competitive therapeutic areas. The panel stresses the importance of linking RWE to financial outcomes and making data relevant to specific patient populations. It's not just about data quality; it's about context and credibility.

Key discussion topics include:

How payers evaluate the financial impact of real-world evidence.
Distinguishing clean trial populations and diverse real-world patients.
Using AI to identify high-response patient populations and refine access.
The role of health equity and demographic alignment in data credibility.